Radiotherapy as an Immunosuppressive Agent for Allotransplantation: Literature Review and Clinical Experience - Past, Present, and Future

Main Article Content

Chuleeporn Jiarpinitnun
Thiti Swangsilpa
Puangpen Tangboonduangjit
Rasin Worawongsakul
Orawan Rattanasuwan

Abstract

Radiotherapy could function as immunosuppressive agent for allotransplantation due to the ability of ionizing radiation to cause cell death, the technique could be applied to irradiate total body, bone marrow and/or lymphoid tissues of the recipient who receive an allograft as an immunosuppressant to improve the success rate of transplantation. From the past to the present, the radiation techniques in allotransplantation process have been continuously studied and developed across preclinical and clinical settings, in order to achieve better therapeutic outcomes. Currently, total lymphoid irradiation by fractionation and total body irradiation with low dose are most frequently used radiotherapy techniques in allotransplantation process. The advanced radiotherapy techniques such as total marrow and/or lymphoid irradiation by volumetric arc therapy (VMAT) or helical tomotherapy (HT) have gained interests. These advanced techniques could increase therapeutic ratio by improving conformity high radiation dose to the targets and reducing dose to the surrounding normal tissues. This review aims to provide the insights of radiotherapy applications as an immunosuppressive agent for allotransplantation and to share clinical experiences and outcomes.


 


 

Article Details

How to Cite
Jiarpinitnun, C., Swangsilpa, T., Tangboonduangjit, P., Worawongsakul, R., & Rattanasuwan, O. (2018). Radiotherapy as an Immunosuppressive Agent for Allotransplantation: Literature Review and Clinical Experience - Past, Present, and Future. Ramathibodi Medical Journal, 41(3), 109-120. https://doi.org/10.14456/rmj.2018.26
Section
Review Articles

References

1. Chinen J, Buckley RH. Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S324-S335. doi:10.1016/j.jaci.2009.11.014.

2. Tami JA, Parr MD, Thompson JS. The immune system. Am J Hosp Pharm. 1986;43:2483-2493.

3. Côté I, Rogers NJ, Lechler RI. Allorecognition. Transfus Clin Biol. 2001;8(3):318-323. doi:10.1016/S1246-7820(01)00121-5.

4. Wouters BG. Cell death after irradiation: how, when and why cells die. In: Joiner MC, van der Kogel A, eds. Basic Clinical Radiobiology. 4th ed. London: Hodder Education; 2009:27-40.

5. Goans RE, Holloway EC, Berger ME, Ricks RC. Early dose assessment following severe radiation accidents. Health Phys. 1997;72:513-518.

6. Strober S, Slavin S, Fuks Z, et al. Transplantation tolerance after total lymphoid irradiation. Transplant Proc. 1979;11:1032-1038.

7. Fuks Z, Strober S, Bahrove AM, Sasazuki T, McMichael A, Kaplan HS. Long term effects of radiation on T and B lymphocytes in peripheral blood of patients with Hodgkin’s disease. J Clin Invest. 1976;58(4):803-814. doi:10.1172/JCI108532.

8. du Toit DF, Heydenrych JJ. Application of irradiation as an immunosuppressive agent. S Afr Med J. 1987;71(7):445-447.

9. Abramson N, Ornitz R, Cavanaugh PJ. The effect of local irradiation on rejection of the transplanted kidney. Radiology. 1974;112(2):413-416. doi:10.1148/112.2.413.

10. Halperin EC, Delmonico FL, Nelson PW, Shipley WU, Cosimi AB. The use of local allograft irradiation following renal transplantation. Int J Radiat Oncol Biol Phys. 1984;10(7):987-990. doi:10.1016/0360-3016(84)90168-8.

11. Halperin EC, Bollinger RR. The role of irradiation in solid organ transplantation. Int J Radiat Oncol Bio Phys. 1988;15(4):979-988. doi:10.1016/0360-3016(88)90135-6.

12. Levitt SH, Royster RL, O’Foughludha FT, et al. Radiation for immunosuppression in human organ transplantation. II. Clinical experience. Acta Radiol Ther Phys Biol. 1971;10(3):329-340.

13. Slavin S, Strober S, Fuks Z, Kaplan HS. Immunosuppression and organ transplantation tolerance using total lymphoid irradiation. Diabetes. 1980;29(Suppl 1):121-123.

14. Mathé G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res. 1965;25(9):1525-1531.

15. Andrews GA. Criticality accidents in Vinca, Yugoslavia, and Oak Ridge, Tennessee. Am J Roentgenol Radium Ther Nucl Med. 1965;93:56-74.

16. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511-533.

17. Shank B, Simpson L. The role of total body irradiation in bone marrow transplantation for leukemia. Bull N Y Acad Med. 1982;58(9):763-777.

18. Thomas ED, Clift RA, Hersman J, et al. Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys. 1982;8(5):817-821. doi:10.1016/0360-3016(82)90083-9.

19. Shank B, Chu FC, Dinsmore R, et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys. 1983;9(11):1607-1611. doi:10.1016/0360-3016(83)90412-1.

20. Deeg HJ, Sullivan KM, Buckner CD, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant. 1986;1(2):151-157.

21. Altschuler C, Resbeut M, Blaise D, et al. Fractionated total body irradiation and bone marrow transplantation in acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys. 1990;19(5):1151-1154. doi:10.1016/0360-3016(90)90220-E.

22. Ringdén O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994;83(9):2723-2730.

23. Ringdén O, Labopin M, Tura S, et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Br J Haematol. 1996;93(3):637-645. doi:10.1046/j.1365-2141.1996.d01-1681.x.

24. Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000;18(2):340-347. doi:10.1200/JCO.2000.18.2.340.

25. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2003;32(6):543-548. doi:10.1038/sj.bmt.1704198.

26. Eapen M, Raetz E, Zhang MJ, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood. 2006;107(12):4961-4967. doi:10.1182/blood-2005-12-4942.

27. Slavin S. Total lymphoid irradiation. Immunology Today. 1987;8(3):88-92. doi:10.1016/0167-5699(87)90852-8.

28. Najarian JS, Ferguson RM, Sutherland DE, et al. Fractionated total lymphoid irradiation as preparative immunosuppression in high risk renal transplantation: clinical and immunological studies. Ann Surg. 1982;196(4):442-452.

29. Salter SP, Salter MM, Kirklin JK, Bourge RC, Naftel DC. Total lymphoid irradiation in the treatment of early or recurrent heart transplant rejection. Int J Radiat Oncol Bio Phys. 1995;30(1):83-88. doi:10.1016/0360-3016(95)00135-L.

30. Wolden SL, Tate DJ, Hunt SA, Strober S, Hoppe RT. Long-term results of total lymphoid irradiation in the treatment of cardiac allograft rejection. Int J Radiat Oncol Biol Phys. 1997;39(5):953-960. doi:10.1016/S0360-3016(97)00504-X.

31. Tallaj JA, Pamboukian SV, George JF, et al. Total lymphoid irradiation in heart transplantation: long-term efficacy and survival-an 18-year experience. Transplantation. 2011;92(10):1159-1164. doi:10.1097/TP.0b013e318231e9d3.

32. Arranz R, Otero MJ, Ramos R, et al. Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy. Bone Marrow Transplant. 1994;13(4):383-387.

33. Gaziev D, Giardini C, Galimberti M, et al. Bone marrow transplantation for transfused patients with severe aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning therapy: long-term follow-up from a single center. Bone Marrow Transplant. 1999;24(3):253-257. doi:10.1038/sj.bmt.1701887.

34. Inamoto Y, Suzuki R, Kuwatsuka Y, et al. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen. Biol Blood Marrow Transplant. 2008;14(1):43-49. doi:10.1016/j.bbmt.2007.06.015.

35. Hongeng S, Pakakasama S, Chuansumrit A, et al. Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients. Am J Hematol. 2007;82(12):1095-1098. doi:10.1002/ajh.21002.

36. Lee YH, Kim JY, Choi BO, Ryu MR, Chung SM. Total lymphoid irradiation based conditioning for hematopoietic stem cell transplantation in severe aplastic anemia. Radiat Oncol J. 2012;30(4):165-172. doi:10.3857/roj.2012.30.4.165.

37. Podgorsak EB, Podgorsak MB. Special procedures and techniques radiotherapy. In: Podgorsak EB, ed. Radiation Oncology Physics: A Handbook for Teachers and Students. Vienna: International Atomic Energy Agency; 2005:505-548.

38. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633. doi:10.1016/j.bbmt.2009.07.004.

39. Hill-Kayser CE, Plastaras JP, Tochner Z, Glatstein E. TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplant. 2011;46(4):475-484. doi:10.1038/bmt.2010.280.

40. Shi M, Li M, Ikehara S. Novel conditioning regimens for bone marrow transplantation. Blood Lymphat Cancer. 2013;3(3):1-9.

41. Mohty M, Malard F, Savani BN. High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: time to rethink? Biol Blood Marrow Transplant. 2015;21(4):620-624. doi:10.1016/j.bbmt.2014.09.010.

42. Hui SK, Kapatoes J, Fowler J, et al. Feasibility study of helical tomotherapy for total body or total marrow irradiation. Med Phys. 2005;32(10):3214-3224. doi:10.1118/1.2044428.

43. Wong JY, Liu A, Schultheiss T, et al. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol Blood Marrow Transplant. 2006;12(3):306-315. doi:10.1016/j.bbmt.2005.10.026.

44. Schultheiss TE, Wong J, Liu A, Olivera G, Somlo G. Image-guided total marrow and total lymphatic irradiation using helical tomotherapy. Int J Radiat Oncol Biol Phys. 2007;67(4):1259-1267. doi:10.1016/j.ijrobp.2006.10.047.

45. Han C, Schultheiss TE, Wong JY. Dosimetric study of volumetric modulated arc therapy fields for total marrow irradiation. Radiother Oncol. 2012;102(2):315-320. doi:10.1016/j.radonc.2011.06.005.

46. Zhang M, Qin N, Jia X, Zou WJ, Khan A, Yue NJ. Investigation on using high-energy proton beam for total body irradiation (TBI). J Appl Clin Med Phys. 2016;17(5):90-98. doi:10.1120/jacmp.v17i5.6223.

47. Bethge WA, Lange T, Meisner C, et al. Radioimmunotherapy with yttrium- 90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood. 2010;116(10):1795-1802. doi:10.1182/blood-2010-02-270538.

48. Swangsilpa T, Kraiphibul P, Hongeng S, et al. Outcomes of total body irradiation - based myeloablative conditioning regimen for allogeneic stem cell transplantation in pediatric leukemia. J Med Assoc Thai. 2017;100(7):748-757.